Meet 2014's Blockbuster Drugs

Introducing next year’s blockbuster drugs

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

November 15, 2013 at 4:36 AM UTC

This article is for subscribers only.

BusinessWeek Cover Image (13_47, 1600x2398)

This article is part of the November 18, 2013 issue of businessweek.

Former EPA Chief Carol Browner's Energy Industry Outlook for 2014

These five medicines are predicted to be big moneymakers:

GA101
Roche’s experimental leukemia drug beat the company’s top seller, Rituxan, in a trial that may position it as the older treatment’s heir. Annual revenue is forecast to reach $1.4 billion in 2018, based on a Bloomberg survey of six analysts.